About
Founded in 1998, Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since its inauguration, Gan & Lee has been focusing on insulin production. In 1998, Gan & Lee successfully developed the first domestic biosynthetic human insulin, which was evaluated as China’s top 10 scientific and technological breakthroughs by Chinese Academy of Sciences and Engineering. Hitherto Gan & Lee has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin®, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25®, all of which have received high reputation from nationwide clinicians and patients, with outstanding efficacy and safety guarantees.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 1,530 investors are based in Beijing, Beijing, China.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Beijing, China
Contact Information
Find more investors like Gan
Search Investors